Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2007-001166-33-DE
EUCTR2007-001166-33-DE
Active, not recruiting
Not Applicable

A prospective, randomised, multicenter clinical trial investigating the reduction of Calcineurin inhibitor toxicity by means of steroid free long-term immune suppression with Ciclosporin A and Mycophenolat mofetil in children and adolescents after kidney transplantation - Recaltox-1

niversitaetsklinikum Erlangen-Nuernberg0 sitesAugust 17, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsSandimmun optoral 10 mg capsulesSandimmun optoral 25 mg capsulesSandimmun optoral 50 mg capsulesSandimmun optoral 100 mg capsulesSandimmun optoral Lösung

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitaetsklinikum Erlangen-Nuernberg
Status
Active, not recruiting
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 17, 2007
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversitaetsklinikum Erlangen-Nuernberg

Eligibility Criteria

Inclusion Criteria

  • •1\.Age at inclusion 3 – 16 years
  • •2\.Male or female patients
  • •3\.Condition after first or second isolated renal transplantation
  • •4\.Graft age \> 24 months
  • •5\.Last acute rejection \> 6 months ago
  • •6\.Immune suppression comedication Mycophenolatmofetil (MMF) in a dose range of 1200 \+/\- 200 mg/m² BSA/d within at least 6 months or minimal MPA\-AUC \= 45 mg x h/l. If MPA\-AUC \< 45 mg x h/l adjustment of dosage with re\-screening in \= 4 weeks is possible.
  • •7\.Steroid free immune suppression within at least 6 months before study inclusion
  • •8\.Application of CSA in stable dosing within the last 3 months before study inclusion and CSA\-C2\-level \> 500 ng/ml. If CSA\-C2\-level \< 500 ng/ml adjustment of dosage with re\-screening in \= 4 weeks is possible.
  • •9\.Preexisting immune suppressive therapy with CSA, therefore contraindications, precautions for use, interactions acc. to product information have already been checked at time of transplantation and do not exist
  • •10\. Biopsy of the kidney graft without signs of an acute rejection (definition acc. to the BANFF classification) within the last 3 months before study inclusion

Exclusion Criteria

  • •1\.GFR \< 40 ml/min/1,73 m² body surface area acc. to Schwartz' formula at study start
  • •2\.More than 2 acute graft rejections within the last 12 months before start of the clinical trial
  • •3\.Condition after steroid resistant rejection in the past
  • •4\.Actual participation in another clinical therapy trial
  • •5\.Proof of a recidive of the basic disease in the renal graft
  • •6\.Patients with proof of EBV\- or CMV\- infection and indication of antiviral therapy within the last 3 months before study inclusion
  • •7\.Patients with proof of manifest Poliomavirus infection within the last 3 months before study inclusion
  • •8\.Pregnancy and lactation
  • •9\.Hemoglobin \< 8 g/dl at screening visit
  • •10\.Untreated arterial hypertonia

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
se of the corifolitropina alfa in oocyte donorsThe study is proposed to determine the level of compliance and pharmacoeconomic impact of three protocols for controlled ovarian stimulation in women participating in oocyte donation programTherapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
EUCTR2014-001743-20-ESIVI Madrid
Active, not recruiting
Not Applicable
A study Protocol for patients with relapsed osteosarcomaHigh malignancy grade of osteosarcoma relapseMedDRA version: 14.1Level: PTClassification code 10031296Term: Osteosarcoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2012-001010-42-ITITALIAN SARCOMA GROUP
Completed
Phase 1
A multicenter randomized clinical study of using a three-dimensional printed patient personalized titanium plate in jaw surgeryManagement of dentofacial deformities through an orthognathic surgical interventionSurgery
ISRCTN11838566West China Hospital of Stomatology, Sichuan University100
Active, not recruiting
Not Applicable
Multicenter, prospective, randomized clinical trial to assess two different doses of anti-human-T-lymphocyte immune serum preparation derived from rabbit in GVHD profilaxis in pediatric population with haematologic malignancies riceiving non allogenic stem cell transplantation. - NDgraft versus host disease profilactic useMedDRA version: 9.1Level: LLTClassification code 10018653Term: Graft-versus-host disease <GVHD>
EUCTR2008-000101-11-ITOSPEDALE POLICLINICO S. MATTEO
Active, not recruiting
Not Applicable
Healing effectiveness of Algosteril vs Aquacel Extra in pilonidal sinuses
ISRCTN24794558Brothier (France)238